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Abstract
Objective: To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood
concentrations.
Methods: We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or
episodic migraineurs and non-headache controls. Subsequent searches retrieved studies with blood measurements of
selected CSF biomarkers. If a compound was assessed in three or more studies, results were pooled in a meta-analysis
with standardised mean differences (SMD) as effect measures.
Results: Sixty-two compounds were measured in 40 CSF studies. Most important results include: increased glutamate
(five studies, SMD 2.22, 95% CI: 1.30, 3.13), calcitonin gene-related peptide (CGRP) (three studies, SMD: 3.80, 95% CI:
3.19, 4.41) and nerve growth factor (NGF) (three studies, SMD: 6.47, 95% CI: 5.55, 7.39) in chronic migraine patients and
decreased b-endorphin (b-EP) in both chronic (four studies, SMD: –1.37, 95% CI: –1.80, –0.94) and interictal episodic
migraine patients (three studies, SMD: –1.12, 95% CI: –1.65, –0.58). In blood, glutamate (interictal) and CGRP (chronic,
interictal and ictal) were increased and b-EP (chronic, interictal and ictal) was decreased.
Conclusions: Glutamate, b-EP, CGRP and NGF concentrations are altered in CSF and, except for NGF, also in blood of
migraineurs. Future research should focus on the pathophysiological roles of these compounds in migraine.
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Introduction
Migraine is a prevalent episodic brain disorder (1). The
World Health Organisation (WHO) rates migraine as
one of the most disabling chronic disorders (2).
Despite extensive research over the last decades,
migraine pathophysiology is not completely understood
(3). Although several compounds (e.g. calcitonin gene-
related peptide (CGRP), glutamate and serotonin) have
been implicated in migraine pathophysiology, our under-
standing of the biochemistry of migraine is still limited
(4,5). Identiﬁcation and validation of biochemical bio-
markers might help us in uncovering pathophysiological
processes involved in migraine, which in turn might lead
to diagnostic tests or new therapeutic strategies (6,7).
The ﬁeld of biochemical biomarker research is
expanding rapidly. Promising biomarkers have been dis-
covered for brain disorders such as Alzheimer’s disease,
narcolepsy, and Parkinson’s disease (8–10).
Cerebrospinal ﬂuid (CSF) is believed to reﬂect
biochemical changes in the brain and therefore is the
body ﬂuid of primary interest for brain disorders (11).
Although many small studies have analysed biochemical
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changes in CSF from migraine patients, results were
often inconsistent and have not led to pathophysio-
logical and diagnostic biomarkers. However, the litera-
ture has never been systematically reviewed with
quantitative synthesis of the evidence. With this ﬁrst
meta-analysis we aimed to identify biochemical migraine
biomarkers which show consistent changes in CSF and
to assess whether these changes are also present in blood.
Methods
Search strategy, study selection and eligibility
criteria
We conducted and reported the review process in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement (12). We performed an electronic search for
published studies up to 16 August 2014 in MEDLINE,
EMBASE and Web of Science on biochemical ﬁndings
in CSF of migraine patients. Medical Subject Heading
(MeSH) terms and free text terms were collated with
the assistance of research librarians at the Leiden
University Medical Centre. The full search string can
be found in Supplement 1.
Two investigators (R.M.D. and R.Z.) independently
assessed titles and abstracts to determine potential eli-
gibility. Disagreement was resolved by discussion. The
same investigators independently assessed the full-text
articles of potentially relevant studies to verify if eligi-
bility criteria were met, and to evaluate whether the
results were adequately reported.
We included case-control studies and case-crossover
studies (same patients studied in between and during
migraine attacks), in which one or more endogenous
compounds (metabolites, peptides, proteins) were quan-
tiﬁed in CSF samples from migraine patients. Case
reports were not considered eligible. Publications on
pharmacological trials were excluded if no endogenous
compounds were measured at baseline. Studies not writ-
ten in English, conference abstracts, editorials and let-
ters were also not eligible. Reference lists of articles
eligible for full-text review and relevant reviews were
additionally searched for potentially relevant studies.
Subsequent search for studies on blood concen-
trations of selected biomarkers
To assess whether CSF biomarkers show similar results
in blood, we performed in a second stage a literature
search for published data on measurements in plasma
and serum. We speciﬁcally searched for studies report-
ing blood concentrations of compounds which had
shown consistent and signiﬁcant diﬀerences in meta-
analysis of CSF data. These additional blood studies
were identiﬁed and selected by performing the same
search and selection process as described for CSF stu-
dies. The full search string for blood is reported in
Supplement 1. After study selection, data were
extracted and subsequently included in study assess-
ment and meta-analysis following the same method-
ology as for CSF.
Data extraction
Data extraction was performed by one investigator
(R.M.D) using a standardised extraction form. A
second investigator (R.Z.) was consulted if discussion
was necessary. Information was extracted on: (1) study
design; (2) study population characteristics (sample size,
age, gender, medication, comorbidity and other poten-
tial confounders) and study groups deﬁnition (diagnostic
criteria, presence of migraine attack during sampling,
presence of chronic migraine component); (3) sampling
methods (fasting, timing and storage temperature),
measurement methods and data analysis; and (4) con-
centrations of endogenous compounds (metabolites,
peptides, proteins) in study (sub)groups, including stat-
istical parameters. To obtain relevant missing informa-
tion of studies included for meta-analysis, we attempted
to contact corresponding authors twice via email.
Risk of bias assessment
To assess risk of bias, we adapted the Newcastle-
Ottowa Scale (13) (Supplement 1). We considered
deﬁnition of cases and controls to be adequate when
published criteria were used for diagnosis of migraine
patients. Selection of cases was adequate when patients
were representative for the deﬁned migraine type
(no severe comorbidity or clinical reasons to sample
body ﬂuids). Selection of controls was adequate when
controls were sampled from the same population as the
cases. Comparability between cases and controls was
assessed based on gender- and age-matching of study
groups (either by design or analysis). Studies ade-
quately describing sampling and measurement methods
and performing measurements according to validated
analytical methods were considered to have low
risk of measurement bias. One investigator (R.M.D.)
assessed selection and comparability, two investigators
(R.M.D. and M.N.) assessed the description and
validity of the measurements, and a third investigator
(R.Z.) was contacted if discussion was necessary.
Group definition
We divided case-control comparisons into episodic
migraine versus controls and chronic migraine versus
controls. If there was no evidence that migraine patients
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had a chronic component, we classiﬁed them as episodic
migraine. Findings in episodic migraine were further
classiﬁed based on migraine state: interictal and ictal.
Migraine with aura patients and migraine without
aura patients were grouped, because results were often
not reported separately for these groups. When applic-
able, ictal versus interictal ﬁndings, from case-control
and from case-crossover studies, were compared.
Meta-analysis: Pooling of results and statistical
procedures
We used standardised mean diﬀerences (SMDs) with
their 95% conﬁdence interval (CI) as the main eﬀect
measure. Compound concentrations were analysed in
meta-analysis if data were available from three or
more studies for one of the deﬁned group comparisons.
The way we have dealt with missing data, irregularities
in the data, and pooling of data was in accordance with
approaches described by the Cochrane Collaboration
(14) (Supplement 1).
For quantitative synthesis, we used the inverse vari-
ance method. We applied a random-eﬀects model by
default given the expected clinical heterogeneity
between studies. However, as the between-study vari-
ation cannot be estimated reliable in case of <5 studies,
we applied a ﬁxed-eﬀects model in these instances.
Homogeneity of eﬀect sizes was assessed using the I2
statistic and by visual inspection of forest plots. To
examine the eﬀect of inclusion of clear heterogeneous
studies, we applied a sensitivity analysis to assess their
speciﬁc eﬀect on the overall eﬀect size. For statistical
analysis we used RevMan 5.2 (Cochrane IMS,
Baltimore, MD, USA).
Results
Study selection and study characteristics
The selection of CSF studies is depicted in the ﬂowchart
(Figure 1). A total of 1197 unique articles were identi-
ﬁed, of which 40 were considered eligible (38 case-
Records identified through
database searching
(n = 1517)
Records after duplicates removed
(n = 1197)
Records screened
(n = 1197)
Full text articles assessed for
eligibility
(n = 124)
Studies included in qualitative
synthesis
(n = 40)
Studies included in quantitative
synthesis (meta-analysis)
(n = 12)
Full text articles excluded (n = 84)a
•    Excluded based on abstract (n = 1072)
•    Review articles (n = 20)
•    No migraine patients included (n = 6)
•    Not in english (n = 3)
•    Editorial comment or letter to the editor (n = 2)
•    Animal experiments (n = 2)
•    Case reports on one migraine patient (n = 2)
•    Pharmocological trial (n = 1)
•    Data not reported for migraine patients (n = 6)
•    Reports on CSF from multiple patients
      without consistency in measurements (n = 4)
•    Conference abstracts (n = 17)
•    No measurements in CSF (n = 10)
•    Unclear quantification and/or quantification of
     enzyme activities (n = 9)
•    Unable to retrieve full text article (n = 1)
Additional records identified
through other sources
(n = 41)
Figure 1. Flowchart of CSF study selection process.
aStudies could be excluded for more than one eligibility criterion. Therefore, overlaps exist between these categories. CSF: cere-
brospinal fluid.
van Dongen et al. 3
control studies and two case-crossover studies).
Investigator agreement on title and abstract screening,
before consensus, was k¼ 0.72. Episodic migraine
patients were sampled for 22 case-control studies and
chronic migraine patients for 16 case-control studies.
The number of cases ranged from 4 to 60 (average: 24)
and the number of controls from 5 to 108 (average: 24).
Description of individual study characteristics can be
found in the electronic supplementary table. Twelve
CSF studies were ﬁnally included in meta-analyses on
compounds that were measured in multiple studies. The
subsequent search for blood studies on selected CSF
biomarkers is illustrated in Supplementary Figure S1.
Risk of bias assessment
Most CSF studies (73%) applied adequate diagnostic
criteria (Table 1); 11 studies that did not report the use
of diagnostic criteria were published before introduc-
tion of the International Classiﬁcation of Headache
Disorders (ICHD-I) (15). Criteria for chronic migraine
(Silberstein (16) and ICHD second edition (ICHD-II)
revision (17)) were applied by all but four studies on
chronic migraine (75%).
Migraine cases were not always deemed representa-
tive for the diagnosed migraine type because lumbar
punctures were performed to exclude other neurologic
diseases (ﬁve studies), migraine patients were admitted
to the hospital for unstated reasons (four studies) or
because recruitment of cases was not clearly reported
(11 studies) (Table 1). Controls often had lumbar punc-
tures for other purposes than migraine patients; either
for other diagnostic purposes (13 studies) or before
spinal anaesthesia (four studies). Based on available
cohort descriptions, only six studies recruited cases
and controls from the same population, of which four
studies were sampled from the general population. For
15 studies it was explicitly stated that controls had no
personal history of migraine (Table 1). Furthermore, a
minority of studies (eight studies) adjusted for age and
gender.
Sampling and measurement methods were ade-
quately described in 22 studies (55%; Table 1). The
older publications especially lacked full and clear
descriptions of methods. Measurement techniques
were considered to be (partially) validated in 21 studies.
Quantitation characteristics (precision, accuracy and
limit of detection) were often not reported.
Biochemical findings
In total, 62 unique compounds have been measured in
CSF from migraine patients (Table 2) (18–55).
Frequently measured compounds (in three or more
Table 1. Summary of study characteristics and risk of bias assessment of CSF studies.
Study characteristics Studies Risk of bias assessment Studies
Publication year Selection Adequate
 1960 1 (3%) Definition of cases 29 (73%)
1961–1980 7 (18%) Selection of cases 20 (50%)
1981–2000 15 (38%) Definition of controls 15 (39%)a
 2001 17 (43%) Selection of controls 6 (16%)a
Study design Comparability
Case-control 38 (95%) Matching for age and gender 8 (21%)a
Case-crossover only 2 (5%) Matching for other factors 4 (11%)a
Migraine types and states Measurements
Episodic migraine 22 (58%)a Measurement description 22 (55%)
Ictal state 19 (50%)a Validation of measurement technique 21 (53%)
Interictal state 13 (34%)a
Mixed state 3 (8%)a
Chronic migraine 16 (42%)a
Control types
Healthy 7 (18%)a
Spinal anaesthesia 4 (11%)a
Diagnostic lumbar punctureb 15 (39%)a
Other neurological diseases 9 (24%)a
Risk of bias assessment: number of studies which were assessed as adequate for the corresponding item. aTotal of 38 studies (excluding two case-
crossover studies since no controls were present). bControls underwent a diagnostic lumbar puncture and, retrospectively, CNS disorders were
excluded by original researchers after which samples were used as control samples. CSF: cerebrospinal fluid.
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Table 2. Overview of published biochemical measurements in CSF from migraine patients.
Studies Chronic migraine Episodic migraine Episodic migraine
N ¼ Interictal Ictal
NEUROTRANSMITTER SYSTEMS
Glutamatergic system
Glutamate 7 "18 "19 "20 "21 "22 u.d.23 u.d.23 "24 u.d.23
Glutamine 1 "23 (")23a (")23a
Glycine 1 "23 (")23a (")23a
Serotonergic system
5-hydroxyindoleacetic acid 4 ¼23 (¼)25 ¼26 (¼)23 (")27a (¼)25 ¼26 (¼)23 (")27a
Tryptophan 2 ¼28 ¼29 "28 "29
5-hydroxytryptamine 1 u.d.23
Dopaminergic system
Homovanillic acid 4 ¼30 ¼23 ¼25 (¼)23 (¼)27 ¼25 (¼)23 (¼)27
3,4-dihydroxyphenylacetic acid 1 "31
Tyrosine 1 ¼31
Epinephrine 1 ¼32
Norepinephrine 1 ¼32
GABAergic system
g-Aminobutyric acid 4 ¼33 u.d.23 u.d.34 u.d.35 u.d.23 (")34 (")35 u.d.23
Cholinergic system
Acetylcholine 1 (")36
NEUROPEPTIDES
Endogenous opioids
b-endorphin 5 #30 #37 #38 #39 #37 #38 #40 #40
b-lipotropin 2 #37 #38 ¼37 ¼38
Adrenocorticotropic hormone 2 ¼37 ¼38 ¼37 ¼38
a-N-acetyl-b-endorphin 1 "30
‘Enkephalins’ 1 ¼28b #28
Met-enkephalin 1 "41c
Tachykinin neuropeptides
Substance P 2 "18 "42
Neurokinin A 1 "18
Other neuropeptides
Calcitonin gene-related peptide 3 "18 "42 "43
Neuropeptide Y 2 ¼40 ¼40 "44
Somatostatin 2 #45 ¼40b #40
Orexin-A 1 "46
ENDOCANNABINOIDS
Anandamide 1 #43
Palmitoylethanolamide 1 "43
2-Arachidonoylglycerol 1 u.d.43
NEUROTROPHINS
Nerve growth factor 3 "20 "21 "42
Brain-derived neurotrophic factor 2 "20 "21
Glial cell-derived neurotrophic factor 1 #45
CYTOKINES
Tumor necrosis factor-alpha 2 "47 u.d.48
Interleukin-1 receptor antagonist 1 "48
(continued)
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studies) are glutamate, b-endorphin (b-EP), 5-hydro-
xyindoleacetic acid (5-HIAA), homovanillic acid
(HVA), CGRP and nerve growth factor (NGF).
Forty-four compounds were measured only once.
Meta-analysis showed that glutamate (Figure 2), b-EP
(Figure 3), CGRP (Figure 4) and NGF (Figure 5) con-
centrations were consistently altered in CSF from
migraine patients compared to controls; results will be
discussed below, together with results on blood concen-
trations. For HVA there was insuﬃcient quantitative
data available for meta-analysis (CSF concentrations
not reported separately for ictal and interictal patients)
and for 5-HIAA CSF studies showed inconsistent
eﬀects (Supplementary Figure S2).
Glutamate (Figure 2)
Glutamate concentrations were increased in CSF from
chronic migraine patients (SMD: 2.22, 95% CI: 1.30,
3.13) (18–22). In blood from interictal episodic
migraine patients the pooled diﬀerence was not statis-
tically signiﬁcant (SMD: 1.08, 95% CI: –0.07, 2.22)
(56–62). After exclusion of paediatric migraine patients
(58), glutamate concentrations were increased in the
Table 2. Continued.
Studies Chronic migraine Episodic migraine Episodic migraine
N ¼ Interictal Ictal
Monocyte chemotactic protein-1 1 "48
Transforming growth factor Beta 1 1 "48
Interleukin-10 1 u.d.48
Interleukin-1b 1 u.d.48
Interleukin-4 1 u.d.48
METAL IONS
Calcium (ionised) 1 ¼49 ¼49
Calcium (total) 1 ¼49 ¼49
Magnesium (total) 1 ¼49 ¼49
Potassium 1 ¼49 ¼49
Sodium 1 ¼49b "49
OTHER
Nitrite products (NO, NO2–, NO3–) 3 "18 "43 ¼44d
Taurine 2 "23 (")23a "50 (")23a
Albumin 1 ¼27 ¼27
Aspartic acid 1 u.d.24
Chromogranin A 1 ¼44
Corticotropin-releasing hormone 1 "46
Cortisol 1 #51
Cyclic adenosine monophosphate 1 "35
Follicle-stimulating hormone 1 (")51
Guanosine 2’,3’-cyclic phosphate 1 "18
Homocysteine (free) 1 ¼52
Homocysteine (total) 1 "52
Immunoglobulin G 1 ¼27 ¼27
Luteinizing hormone 1 (")51
Methionine 1 #52
Neuron-specific enolase 1 (¼)53
Phosphatidylcholine-specific phospholipase C 1 ¼54b ¼55 "54
Prolactin 1 (")51
Published biochemical findings in migraine patients compared with controls. "¼ significantly elevated concentrations, # ¼ significantly decreased
concentrations, ‘‘¼‘‘ ¼ similar concentrations, between () ¼ no statistical analysis reported, u.d. ¼ undetectable concentrations reported for
studied migraine group. aSignificant when interictal and ictal groups were pooled. bSignificant difference between ictal and interictal migraine patients
reported. cMigraine state not reported. dNitric oxide (NO) was measured; not reported if NO2
– and NO3
– were also quantified. Excluding glucose
from the routine CSF measurements (nine studies reported normal glucose concentrations in migraine patients). CSF: cerebrospinal fluid.
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remaining adult migraineurs (SMD: 1.61, 95% CI:
0.73, 2.49). Glutamate concentrations were increased
in CSF from ictal patients (SMD: 2.01, 95% CI: 1.27,
2.75) (24). In blood, two studies showed clearly oppos-
ing results on ictal measurements and therefore we did
not perform a meta-analysis (24,56). There are no stu-
dies on glutamate concentrations in blood from chronic
migraine patients and in CSF from interictal
migraineurs.
-Endorphin (Figure 3)
b-EP concentrations were decreased in CSF (SMD: –
1.37, 95% CI: –1.80, –0.94) (30,37–39) and blood
Chronic migraine
CSF
CSF
CSF
Blood
Ferrari, MD et al. 1990
Cananzi et al. 1995
Ferrari, MD et al. 1990
Martinez et al. 1993
D'Eufemia et al. 1997 (PM)
Alam et al. 1998
Vaccaro et al. 2007
Ferrari, A et al 2009*
Campos et al. 2013
Blood
Blood
Cases Controls SMD (95% CI)
Episodic migraine - Interictal
Episodic migraine - Ictal
No studies published
No studies published
Sarchielli et al. 2002
I2 = 85%
Pooled estimate: Z = 4.75
P < 0.0001
I2 = 96%
Pooled estimate: Z = 1.93
P = 0.07
Sensitivity analysis
Martinez et al. 1993
Sarchielli et al. 2007 (I)
Gallai et al. 2003
Peres et al. 2004
Viera et al. 2007
Cases Controls
N= Mean SD N= H Weight
SMD (95% CI) SMD (95% CI)
Random-effectsMean SDAge Fem Age FemMO
25
25
30
19
20
2.7
2.21
0.25
0.289
2.18
0.5
0.26
0.186
0.177
0.40
46.5
44.7
42.3
42.9
38.4
18
16
14
13
16
NR
NR
NR
NR
NR
20
20
20
19
20
1.4
1.00
0.041
0.109
1.37
0.3
0.25
0.186
0.066
0.30
44.9
44.6
NR
NR
41.6
13
13
NR
NR
15
N
N
N
N
N
19.5%
18.7%
21.1%
20.8%
20.0%
3.02 [2.14, 3.89]
3.61 [2.64, 4.59]
1.10 [0.43, 1.77]
1.32 [0.61, 2.03]
2.25 [1.44, 3.05]
109
328
Excluding serum (S): I2 = 97%, Z=1.70, P = 0.09
Excluding pediatric migraine (PM): I2 = 92%, Z=3.58, P = 0.0003
166 100.0%
1.18 [–0.18, 2.54]
1.61 [0.73, 2.49]
1.08 [–0.07, 2.22]
99 100% 2.22 [1.30, 3.13]
N= Mean SD Age Fem MO N= Mean SD Age Fem H Weight Random-effects
Cases Controls
Cases Controls
SMD (95% CI)
N= Mean SD Age Fem MO N= Mean SD Age Fem H Weight
N= Mean SD Age Fem MO N= Mean SD Age Fem H Weight
Unpooled
SMD (95% CI)
Unpooled
P
P
P
P
P
P
S
31
57
34
89
50
22
45
62.9
15.80
24.60
481.9
35.4
61.79
153.7
19.5
8.38
6.73
126.1
8.1
18.75
68.6
42.5
28.5
10.4
NR
35.5
33.6
37.3
26
28
18
75
33
NR
44
21
25
19
80
25
22
33
9
19
16
62
20
24
16
31.7
14.60
41.90
277.0
20.7
9.36
121.5
19.5
7.76
8.69
87.0
4.3
2.10
59.2
22.8
35
10.6
NR
38
33.3
31.2
9
9
8
43
12
20
15
Y
Y
Y
Y
Y
Y
Y
14.0%
14.6%
14.1%
14.8%
14.4%
13.5%
14.5%
1.57 [0.74, 2.39]
0.14 [–0.38, 0.66]
–2.30 [–3.06, –1.54]
1.82 [1.44, 2.21]
2.01 [1.39, 2.63]
3.95 [2.93, 4.97]
0.48 [–0.10, 1.06]
25
P
P
31
26
84.5
0.56
19.5
0.22
42.5
38/39 18/19 15 21 0.98 0.64 50.0 8
26 21 9 31.7 19.5 22.8 9 Y
N
NA
NA
0.328 0.074 38/39 17/19 15 19 0.18 0.07 49/50 6/8 N NA 2.01 [1.27, 2.75]
2.65 [1.69, 3.62]
–0.90 [–1.51, –0.30]
–4 –2 0 2 4
Lower Higher
Figure 2. Forest plot of glutamate concentrations in migraine patients and controls.
The squares represent effect sizes of the individual studies (size reflects the weight of the study) and the horizontal lines indicate the
95% confidence intervals (CI). The filled diamonds represent the overall effect size (horizontal width indicates the 95% CI). Age: mean
age; Fem: number of females; MO: number of cases with migraine without aura; H: healthy controls; Y: yes; N: no; NR: not reported;
P: plasma concentrations; S: serum concentrations; CSF: cerebrospinal fluid. *Migraine state is not explicitly reported for this study,
the interictal state was assumed. PM: paediatric migraine patients and paediatric controls. Additional information on the handling of
missing data (e.g. calculations, assumptions) can be found in the supplement.
van Dongen et al. 7
Chronic migraine
Episodic migraine - Interictal
CSF
CSF
Blood
Facchinetti et al. 1981 *
Baldi et al. 1982
Fettes et al. 1985
Awaki et al. 1989
vd Helm et al. 1990 (PM) *
Vécsei et al. 1992
Vécsei et al. 1992
Baldi et al. 1982
Vécsei et al. 1992
Battistella et al. 1996 (PM)
Facchinetti et al. 1989 (MM) *
Nappi et al. 1985 (I) *
Facchinetti et al. 1986 (MM) *
Facchinetti et al. 1983 (PM) *
Blood
P < 0.0001
43
53
25
81
56
83 100.0%
100.0%
100.0%
–1.37 [–1.80, –0.94]
–0.76 [–1.17, –0.36]
–1.12 [–1.65, –0.58]
147
P
P
Sensitivity analysis Excluding serum (S): I2 = 9%, Z=2.97, P = 0.03
Excluding pediatric migraine (PM): I2 = 0%, Z=2.25, P = 0.02
Excluding menstrual migraine (MM): I2 = 8%, Z=3.20, P = 0.001
172 100.0% –0.40 [–0.64, –0.16]
–0.39 [–0.65, –0.13]
–0.32 [–0.59, –0.04]
–0.42 [–0.68, –0.16]
–0.33 [–0.99, 0.32]
I2 = 70%
Cases
N=
6
8
14
15
14.8
17.0
17.79
9.8
9.8
10.47
10.34
9.4
44.8
NR
NR
46
N=SD Age Fem MO
Controls SMD (95% CI)
Cases Controls SMD (95% CI)
Cases Controls SMD (95% CI)
Cases Controls SMD (95% CI)
CSF
Episodic migraine - Ictal
Blood
Cases Controls SMD (95% CI)
Cases Controls SMD (95% CI)
SMD (95% CI)
Mean SD Age Fem H Fixed-effectsWeightMean
N= N=SD Age Fem MOMean SD Age Fem H Fixed-effectsWeightMean
N= N=SD Age Fem MOMean SD Age Fem H Fixed-effectsWeightMean
N= N=SD Age Fem MOMean SD Age Fem H Fixed-effectsWeightMean
N= N=SD Age Fem MOMean SD Age Fem H UnpooledWeightMean
N= N=SD Age Fem MOMean SD Age Fem H UnpooledWeightMean
Genazzani et al. 1984
Genazzani et al. 1984
Nappi et al. 1985 (I)
Nappi et al. 1985 (I)
Nappi et al. 1985 (I)
Vecsei et al. 1992
Martignoni et al. 1989
Misra et al. 2013
Nappi et al. 1985 (II)
Facchinetti et al. 1992
2
NR
NR
11
NR
NR
NR
15
15
30
16
22
86.1
86.1
65.8
15.7
37.0
50.92
26.6
9.7
38.1
NR
NR
43
NR
NR
NR
9
Y
Y
N
N
13.1%
25.3%
20.7%
40.9%
–2.13 [–3.31, –0.94]
–1.47 [–2.33, –0.62]
–2.26 [–3.20, –1.31]
–0.60 [–1.27, 0.07]
Pooled estimate: Z = 6.23
P = 0.0002
I2 = 28%
Pooled estimate: Z = 3.69
P = 0.0002
I2 = 0%
Pooled estimate: Z = 3.31
P < 0.0001
I2 = 73%
Pooled estimate: Z = 4.20
P < 0.0001
I2 = 0%
Pooled estimate: Z = 4.09
P
P
P
11
25
17
4.7
4.79
3.74
2.3
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Figure 3. Forest plot of b-EP concentrations in migraine patients and controls.
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Figure 4. Forest plot of CGRP concentrations in migraine patients and controls.
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(SMD: –0.76, 95% CI: –1.17, –0.36) (38,63,64) from
chronic migraine patients. Concentrations were also
decreased in CSF (SMD: –1.12, 95% CI: –1.65, –0.58)
(37,38,40) and blood (SMD: –0.40, 95% CI: –0.64, –
0.16) (38,40,65–73) from interictal patients. Pooled esti-
mates remained similar in sensitivity analysis. One
blood study was excluded from meta-analysis because
the assay that was used had a very high cross-reactivity
with b-lipotropin (28). In ictal migraineurs b-EP con-
centrations were decreased in CSF (SMD: 1.39, 95%
CI: –2.40, –0.39) (40) and blood (SMD: –1.44, 95% CI:
–2.11, –0.77) (40,66).
CGRP (Figure 4)
CGRP concentrations were increased in CSF
(SMD: 3.80, 95% CI: 3.19, 4.41) (18,42,43) and blood
(SMD: 0.70, 95% CI: 0.45, 0.95) (74–77) from chronic
migraine patients, and in blood from interictal
(SMD: 0.47, 95% CI: 0.20, 0.75) (74,76–83) and ictal
(SMD: 0.79, 95% CI: 0.49, 1.09) (78,82–84) episodic
migraineurs. Sensitivity analysis had small eﬀects
on pooled estimates. There are no studies on
CGRP concentrations in CSF from episodic migraine
patients.
NGF (Figure 5)
Concentrations of NGF were increased in CSF (SMD:
6.47, 95% CI: 5.55, 7.39) (20,21,42) and blood (SMD:
1.08, 95% CI: 0.58, 1.59) (75) from chronic migraine
patients. Blood concentrations were not signiﬁcantly
diﬀerent in interictal patients (SMD: 0.06, 95% CI: –
0.31, 0.42) (85). There are no studies published on ictal
concentrations (CSF and blood) and interictal concen-
trations in CSF.
Discussion
We conducted a systematic review and meta-analysis
of biochemical measurements in CSF from chronic
and episodic migraineurs. Meta-analysis showed
increased concentrations of glutamate and CGRP and
decreased concentrations of b-EP in CSF. These
changes are also present in blood – a more accessible
body ﬂuid. Concentrations of NGF were increased in
CSF from chronic migraine patients but blood data
were limited.
Increases in glutamate and CGRP are in agreement
with theories on pathophysiological mechanisms for
migraine (4,5). Glutamate is the principal excitatory
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Figure 5. Forest plot of NGF concentrations in migraine patients and controls.
The squares represent effect sizes of the individual studies (size reflects the weight of the study) and the horizontal lines indicate the
95% confidence intervals (CI). The filled diamonds represent the overall effect size (horizontal width indicates the 95% CI). NGF:
nerve growth factor; Age: mean age; Fem: number of females; MO: number of cases with migraine without aura; H: healthy controls; Y:
yes; N: no; NR: not reported; P: plasma concentrations. Additional information on the handling of missing data (e.g. calculations,
assumptions) can be found in the supplement.
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neurotransmitter within the central nervous system and
has been linked to neuronal hyperexcitability in
migraine (86). Glutamate has been implicated in the
onset and generation of cortical spreading depression
(CSD), which is believed to be the underlying cause of
migraine aura. Increased synaptic glutamate concen-
trations lower the threshold for CSD (5). CGRP has
been implicated as a mediator which activates and
sensitises peripheral meningeal nociceptors causing
migraine headache (4). Trigeminal ﬁbres surrounding
meningeal vessels release CGRP and other neuropep-
tides, and there is increasing evidence that CSD can
initiate this release in animal experiments (5).
Another rat model showed that CGRP released by
primary trigeminal aﬀerents impacts both CSF and
blood concentrations and that the contribution of
non-trigeminal structures to CSF concentrations is
only minor (87).
In CSF from chronic migraine patients, NGF is
increased with glutamate and CGRP. NGF is not
only a well-known growth factor, but, following tissue
injury, also an inducer of hyperalgesia via diﬀerent per-
ipheral mechanisms including mast cell degranulation
(88). After local injury or inﬂammation both peripheral
(reactivated Schwann cells, non-neural cells) and cen-
tral (neurons, astrocytes, microglia) sources upregulate
NGF expression (89). In contrast to CGRP, their rela-
tive contributions to CSF composition are still
unknown. Additionally, NGF can upregulate CGRP
expression in sensory and motor neurons (90,91).
In one included CSF study NGF and CGRP con-
centrations were indeed positively correlated (42).
Furthermore, by upregulating synthesis of brain-
derived neurotrophic factor (BDNF), NGF can
enhance synaptic transmission via N-methyl-D-
aspartate receptors (92,93). Primarily the latter is hypoth-
esised to contribute to chronic sensitisation of central
neurons (i.e. in the nucleus trigeminus) (19–22). It is
believed that this process also occurs in other chronic
pain disorders such as ﬁbromyalgia, where increased
CSF concentrations of NGF, BDNF and glutamate
have been found (21). This indicates that the observed
changes are possibly not speciﬁc for migraine and
instead reﬂect exposure to chronic pain.
b-EP concentrations are decreased in CSF and blood
both from interictal patients and chronic migraine
patients. Low b-EP concentrations have been hypoth-
esised to reﬂect low analgesic activity in individuals.
However, recent evidence suggests chronic pain
patients with low b-EP concentrations have stronger
analgesic activity when in pain through rapid upregula-
tion of b-EP (94). In analgesic research with migraine
patients b-EP could be a useful marker to study in more
detail.
Study strengths and limitations
The main strength of this study is the systematic
approach to the identiﬁcation, quality assessment and
analysis of published data. However, our ﬁndings
should be interpreted in the light of the limitations of
the included evidence.
We found considerable clinical and methodological
heterogeneity across studies. Statistical heterogeneity
was also observed in meta-analysis of glutamate, b-EP
and CGRP, but importantly all studies showed an eﬀect
in the same direction. Nonetheless, diversity in migraine
patients was present due to diﬀerences in migraine fre-
quency, timing of measurements and diagnostic criteria.
Less diversity was present in CSF studies on CGRP and
NGF, since the studies were performed at the same
headache centre (new participants with approximately
similar clinical characteristics (age, gender, disease his-
tory, headache frequency and medication overuse) were
recruited for each study; conﬁrmed with original inves-
tigators). Furthermore, migraine patients were not
always representative for the diagnosed migraine type
because samples were taken for diagnostic purposes (i.e.
other neurological disorders were suspected). Diversity
in controls seemed primarily related to the availability of
samples as well. Control cohorts often consisted of non-
healthy controls in whom samples were collected for
other diagnostic purposes than the migraine patients;
this is especially the case for CSF studies where collec-
tion in healthy individuals is often not possible.
Additionally we found that the quality of reporting
was inconsistent. Studies particularly failed to specify
the validation, sensitivity and monitoring of applied
measurement technique. Additionally, group compari-
sons were not always clearly reported and applied stat-
istical analysis was frequently not well explained.
Therefore, despite our attempts to contact correspond-
ing authors, we were not able to retrieve all required
data and had to apply published methods to calculate
or estimate these data (14).
Publication bias is probably a major issue in the
reporting of biomarker studies, because negative ﬁnd-
ings are less likely to get published (95). However, we
did not generate funnel plots to assess any publication
bias because the power of this strategy is low with the
relative small number of studies per compound.
Recommendations
Future research should further clarify the pathophysio-
logical relevance of the altered glutamate, b-EP, CGRP
and NGF concentrations in migraine. For better under-
standing of involved biochemical processes, and for
potential application as diagnostic biomarkers, it is
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also important to know whether concentrations are
altered in all migraine types and whether similar
changes are present in other headache disorders and
chronic pain disorders.
Article highlights
. This is the ﬁrst meta-analysis of biochemical measurements in cerebrospinal ﬂuid (CSF) and blood from
chronic and episodic migraine patients.
. A total of 62 unique compounds have been measured in CSF from migraine patients.
. Glutamate, calcitonin gene-related peptide and nerve growth factor (NGF) concentrations are increased and
b-endorphin concentrations are decreased in CSF from migraine patients.
. These changes are also present in blood, with the exception of NGF.
. The presented data identify clear biomarker targets for future pathophysiological or diagnostic studies on
migraine.
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